Market Place
Sourcing Support
Aileron Therapeutics Reports Q3 2024 Results & Highlights
14 Nov 2024 //
PR NEWSWIRE
Aileron Reports Positive Phase 1b Data for IPF Drug LTI-03
13 Nov 2024 //
PR NEWSWIRE
Aileron & Advancium Announce Deal for ALRN-6924 in Retinoblastoma
31 Oct 2024 //
PR NEWSWIRE
Aileron Therapeutics To Present LTI-03 Data In Pulmonary Fibrosis
12 Oct 2024 //
PR NEWSWIRE
Aileron Completes Enrollment In LTI-03 IPF Phase 1b Trial
23 Sep 2024 //
PR NEWSWIRE
Aileron Reports Q2 2024 Results And Business Highlights
14 Aug 2024 //
PR NEWSWIRE
Aileron Therapeutics To Present At Canaccord Genuity Growth Conference
30 Jul 2024 //
PR NEWSWIRE
Aileron Therapeutics to be Included in the Russell Microcap® Index
01 Jul 2024 //
PR NEWSWIRE
Aileron Therapeutics Reports Q1 2024 Financial Results, Business Highlights
15 May 2024 //
GLOBENEWSWIRE
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
06 May 2024 //
GLOBENEWSWIRE
Aileron Closes $40M Underwritten Registered Direct Offering
03 May 2024 //
GLOBENEWSWIRE
Aileron: Positive IPF Data From LTI-03 Phase 1b Trial Cohort 1
01 May 2024 //
GLOBENEWSWIRE
Aileron Prices $40M Direct Offering At-The-Market Per Nasdaq
01 May 2024 //
GLOBENEWSWIRE
Aileron Q4 & FY 2023 Results, Business Update
15 Apr 2024 //
GLOBENEWSWIRE
Aileron Therapeutics Announces CEO Transition
12 Mar 2024 //
GLOBENEWSWIRE
Aileron & Pulmonary Care Experts To Discuss the Potential Implications of LTI-03
15 Feb 2024 //
GLOBENEWSWIRE
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
01 Feb 2024 //
GLOBENEWSWIRE
Aileron Therapeutics Announces Acquisition of Lung Therapeutics
31 Oct 2023 //
PR NEWSWIRE
Ailing Aileron enters endgame as cancer data trigger layoffs
22 Feb 2023 //
FIERCE BIOTECH
Aileron Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial
21 Feb 2023 //
GLOBENEWSWIRE
Cancer biotech ends trial, searches for sale or other route
21 Feb 2023 //
ENDPTS
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
30 Nov 2022 //
GLOBENEWSWIRE
Aileron Therapeutics Reports 3Q 2022 FYR and Business Highlights
01 Nov 2022 //
GLOBENEWSWIRE
Aileron Presents Results from PI Study in Volunteers Demonstrating ALRN-6924
26 Oct 2022 //
GLOBENEWSWIRE
Aileron Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924
30 Sep 2022 //
GLOBENEWSWIRE
Aileron Therapeutics to Present and Participate in a Fireside Chat at the
22 Sep 2022 //
GLOBENEWSWIRE
Aileron Therapeutics to Present at the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Aileron Therapeutics Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Aileron Is Pleased to Outline Strategy to Strengthen PIb Trial of ALRN-6924
01 Aug 2022 //
GLOBENEWSWIRE
Aileron to Participate in Fireside Chat at the William Blair Conference 2022
08 Jul 2022 //
GLOBENEWSWIRE
Aileron Tx Announces Interim Data from PIb Chemoprotection Trial of ALRN-6924
29 Jun 2022 //
GLOBENEWSWIRE
Aileron Begins Treatment in PIb Trial of ALRN-6924 in Neoadjuvant Breast Cancer
19 May 2022 //
GLOBENEWSWIRE
Aileron Therapeutics to Present at the H.C. Wainwright Conference
17 May 2022 //
GLOBENEWSWIRE
Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022
13 May 2022 //
GLOBENEWSWIRE
Aileron Therapeutics Announces Late-Breaking Oral Presentation of ALRN-6924
10 May 2022 //
GLOBENEWSWIRE
Aileron Therapeutics Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Aileron Expands Management Team with Appointment of Christopher Zergebel As VP
21 Apr 2022 //
GLOBENEWSWIRE
Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
Aileron Tx to Participate in Maxim Group 2022 Virtual Growth Conference
22 Mar 2022 //
GLOBENEWSWIRE
Aileron Therapeutics to Present at Upcoming Investor Conferences
04 Jan 2022 //
GLOBENEWSWIRE
Aileron Issues Statement on Passing of Scientific Advisory
20 Dec 2021 //
BIOSPACE
Aileron Issues Statement on Passing of Scientific Advisory Board Member
20 Dec 2021 //
GLOBENEWSWIRE
Aileron Reports Q3 2021 Financial Results and Business Highlights
12 Nov 2021 //
GLOBENEWSWIRE
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021
16 Sep 2021 //
GLOBENEWSWIRE
Aileron Presents Data from Ongoing Healthy Volunteer Study of ALRN-6924
27 Aug 2021 //
GLOBENEWSWIRE
Aileron to Participate in Fireside Chat at William Blair Focus Conference 2021
08 Jul 2021 //
GLOBENEWSWIRE
Aileron Announces Initiation of Randomized, Double-Blind Trial of ALRN-6924
01 Jul 2021 //
GLOBENEWSWIRE
Aileron Therapeutics to be Added to the Russell Microcap® Index
24 Jun 2021 //
GLOBENEWSWIRE
Aileron Announces Enrollment Expansion for Upcoming Phase 1b Trial of ALRN-6924
02 Mar 2021 //
GLOBENEWSWIRE
Aileron Therapeutics Announces Completion of $35.9 M Registered Direct Offering
11 Jan 2021 //
BIOSPACE
Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924
12 Oct 2020 //
GLOBENEWSWIRE
Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 M
21 Sep 2020 //
BIOSPACE
Aileron Announces Completion of Enrollment Dose Optimization Expansion Cohort
03 Aug 2020 //
GLOBENEWSWIRE
Aileron Therapeutics Announces Closing of Public Offering of Common Stock
10 Jun 2020 //
GLOBENEWSWIRE
Aileron Announces Positive Interim Results from Ph1b/2 Trial of ALRN-6924
01 Jun 2020 //
GLOBENEWSWIRE
Aileron Announces Initiation of Expansion Ph 1b/2 Study of ALRN-6924
27 May 2020 //
GLOBENEWSWIRE
